REPLIGEN CORP (RGEN)
US7599161095 - Common Stock
Notable Two Hundred Day Moving Average Cross - RGEN
Relative Strength Alert For Repligen
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life...
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of...
Repligen Larger Than S&P 500 Component Bio-Techne
Interesting RGEN Put And Call Options For January 2025
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET...
Noteworthy Monday Option Activity: ADM, NFE, RGEN
Danaher stock rises as Sartorius beats in Q4 (NYSE:DHR)
U.S. life sciences toolmakers Danaher (DHR), Repligen (REGN), and Bio-Rad (BIO) see gains as German peer Sartorius (SARTF) posts strong Q4 2023 results. Read more here.
Commit To Purchase Repligen At $170, Earn 37.3% Annualized Using Options
Noteworthy Friday Option Activity: GM, RGEN, LUV
How Good Is Your Market Cap Knowledge?
A company with a $50 price per share might have a million shares outstanding or a billion shares outstanding. And unless you know, you don't know the price tag of the stock you're about to buy.
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
Repligen to issue $600M convertible senior notes (NASDAQ:RGEN)
Repligen announces $600M convertible senior notes issuance, boosting its year-end cash and cash equivalent guidance to $717M-$727M.
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately...
Repligen Larger Than S&P 500 Component Universal Health Services
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
- Targeting ADC and Cell & Gene Therapy Customers -...
A New Bull Market Is Coming! 3 Stocks Set to Soar 65% to 132% Higher
Wall Street has high hopes for these stocks to buy for the next bull market. Consider adding them to your portfolio.
Repligen beats top and bottom line estimates, narrows FY guidance (NASDAQ:RGEN)
Repligen press release (RGEN): Q3 Non-GAAP EPS of $0.23 beats by $0.07. Revenue of $141.2M (-29.6% Y/Y) beats by $0.55M. Orders strengthened with total book-to-
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of...
Revvity's disappointing Q3 report weighs on life sciences tool stocks (NYSE:RVTY)
Revvity (RVTY) plunged to a 52-week low, dragging down other life science tool providers, after the company released a disappointing Q3 report and cut its forecast. Read more here.